-
Mashup Score: 2
Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated with a poor prognosis, as are high-risk cytogenetic features and failure to achieve a complete response. During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Beksac discussed developing a scoring system to predict early relapse following auto-HSCT for patients with multiple myeloma (MM) in the EBMT database who were treated with 200 mg/m2 melphalan (Mel200) or 140 mg/m2 melphalan (Mel140).
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0How does CAR T-cell therapy compare with allo-SCT for treating R/R LBCL? - 10 month(s) ago
The Lymphoma Hub was pleased to speak to the president of EBMT, Anna Sureda, Catalan Institute of Oncology, Barcelona, ES.
Source: lymphomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📽️ The Lymphoma Hub was pleased to speak to the president of @TheEBMT, Anna Sureda. We asked, How does CAR T cell therapy compare with allo-SCT for treating R/R LBCL? Click here to see what was said 👉 https://t.co/UWC3ivoSqk. #EBMT23 #leusm #lymsm
-
-
Mashup Score: 0Using MRD negativity to measure depth of response & to discontinue treatment in multiple myeloma - 11 month(s) ago
Meral Beksac, MD, comments on the use of measurable residual disease (MRD) to measure depth of response and to guide…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EBMT23 | @mbeksac56 of @AnkaraUni_en comments on using MRD to measure depth of response & guide treatment discontinuation in myeloma. Watch here: 🎥 https://t.co/FByTmbdjdT #MMsm @TheEBMT
-
-
Mashup Score: 0The importance of addressing patients’ fear of progression and relapse - 11 month(s) ago
Lorna Warwick, BA, Lymphoma Coalition, Toronto, Canada, emphasizes the importance of addressing cancer patients’ fear of disease progression and relapse,…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EBMT23 | @LornaWarwick of @knowyournodes discusses the importance of addressing patients' fear of disease progression and relapse & the value of communicating these: 🎥 https://t.co/gNxMpgF9nc @TheEBMT #NCSD2023 #HemOnc
-
-
Mashup Score: 0EBMT 2023 - 11 month(s) ago
Catch up with our live Twitter coverage from the EBMT Meeting, 2023.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🚨 #EBMT23 | In case you missed the @AML_Hub content from @TheEBMT 2023! You can catch up via the link below 👇 https://t.co/YVflqia1oj #AML #leukemia https://t.co/aSxqNaMJfL
-
-
Mashup Score: 0Targeting tumor cells through non-viral Sleeping Beauty transposon engineered CD19-CAR-NK cells - 11 month(s) ago
In this video, Tobias Bexte, Goethe University Frankfurt, Frankfurt, Germany, comments on the design, safety, and efficacy of non-viral Sleeping…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EBMT23 | CAR-NK cells represent a promising new approach to target tumor cells. Check out our interview with @TobiasBexte (@Ullrich_Lab; @FCI_health) on using the Sleeping Beauty transposon to engineer CD19-CAR-NK cells: 🎥 https://t.co/eMzkAqzQS3 @TheEBMT #HemOnc #NCRM23
-
-
Mashup Score: 0Transplant Sessions: EBMT 2023 GvHD Highlights | VJHemOnc - 11 month(s) ago
Good, good day, everybody. My name is Zina Peric and Nico Gagelmann and myself will discuss some of the highlights of the EBMT and we wanted to particularly focus on GVHD. So um I think one of the big, big surprises and I think a very interesting study that we saw at the presidential symposium and also was the winner of the Van Bekkum Award was the study presented, by Yngvar Floisand who…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Missed #EBMT23? Watch @zina_peric and @NicoGagelmann share their #GvHD highlights from this year's meeting! ⬇️ https://t.co/F6ITuYH4Vw #BMTsm #HemOnc https://t.co/lISInqmj9i
-
-
Mashup Score: 0ST2 and REG3α as predictive biomarkers for GvHD - 11 month(s) ago
James Ferrara, MD, DSc, Icahn School of Medicine at Mount Sinai, New York City, NY, outlines currently used biomarkers for…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EBMT23 | James Ferrara (@IcahnMountSinai) gives an overview of predictive biomarkers currently used for GvHD, including ST2 and REG3α. Find out more below: 👉 https://t.co/cL1KtNlGS8 👈 @TheEBMT #BMTsm #HemOnc
-
-
Mashup Score: 0A novel composite endpoint of toxicity and PFS in patients with R/R FL treated with axi-cel - 12 month(s) ago
Razan Mohty, MD, Moffitt Cancer Center, Tampa, FL, summarizes the key points of a study evaluating a novel composite endpoint…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#EBMT23 | @Razan_Mohty (@MoffittNews) discusses a study evaluating a novel composite endpoint of toxicity and PFS in patients with R/R follicular lymphoma treated with axi-cel. Watch now: 👉https://t.co/iYjKpQvFbM👈 @TheEBMT #LymSM #CARTcell #ImmunoOnc
-
-
Mashup Score: 0Approved & emerging JAK inhibitors for patients with high-risk MF who are transplant-ineligible - 12 month(s) ago
Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, outlines treatment options for patients with high-risk myelofibrosis…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Check out our interview with @jjkiladjian, who shares some insights into approved and emerging JAK inhibitors for patients with high-risk, transplant-ineligible myelofibrosis: 🎥 https://t.co/cjSrJbLQD1 @TheEBMT #EBMT23 #MPNsm #HemOnc
-
Have you read this yet? @mbeksac56 discussed a new scoring system for risk of early relapse in patients with #myeloma at #EBMT22. 📝 Find the write-up here, with a closer look at high-risk patients. 👇 👉 https://t.co/dGHB5el37H 👈 #mmsm #bmtsm @EBMT #EBMT23 https://t.co/lz3dYidGh9